Page 2 - Molecular Targeting Technologies Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 11, 2021     WEST CHESTER, Pa. (BUSINESS WIRE) Molecular Targeting Technologies, Inc.   (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99mTc-Duramycin), in patients with advanced colorectal cancer (CRC) . Colorectal cancer is the third most commonly diagnosed malignancy in the world and the second leading cause of cancer death in the United States. While a range of novel active agents has improved the prognosis of patients with colorectal cancer, 50% of advanced colorectal cancer patients die from metastatic disease.

United statesSigrid stroobantsChris pakMolecular targeting technologies incEuropean federal agency for medicinesNuclear medicineNational institutes of healthUniversity of antwerpHealth productsTargeting technologiesClinical trial applicationEuropean federal agencyNational institutesNational cancer instituteஒன்றுபட்டது மாநிலங்களில்கிறிஸ் பக்